Veru has received agreement from the FDA for its planned Phase I/II study to assess VERU-111 in patients with metastatic castration-resistant prostate cancer who are resistant to or do not respond adequately to Pfizer's Xtandi, or enzalutamide, or Johnson & Johnson's Zytiga, or abiraterone acetate. The firm intends to file an investigative new drug application and launch the study by the end of the year.
FDA backs Veru's study of drug for treatment-resistant prostate cancer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.